| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| AXILAXIL Brands, Inc. | 52.99M | 7.79 | 77.90 | -4.51% | 3.26% | 8.85% | 2.9% | 0.08 |
| ULUnilever PLC | 141.09B | 64.70 | 28.25 | 1.94% | 10.16% | 61.19% | 5.51% | 1.36 |
| CLColgate-Palmolive Company | 66.87B | 82.96 | 23.64 | 3.31% | 14.47% | 234.81% | 5.3% | 15.65 |
| PGThe Procter & Gamble Company | 337.05B | 144.24 | 22.16 | 0.29% | 19.74% | 31.31% | 4.17% | 0.68 |
| SLSNSolesence, Inc. Common Stock | 107.22M | 1.52 | 21.71 | 40.35% | 1.72% | 6.21% | 1.02 | |
| EPCEdgewell Personal Care Company | 861.43M | 18.44 | 9.36 | 0.09% | 2.94% | 4.13% | 20.26% | 0.87 |
| UGUnited-Guardian, Inc. | 28.76M | 6.26 | 8.82 | 11.91% | 19.48% | 18.52% | 10.55% |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 14.01M | 10.78M | 12.97M | 13.77M | 13.6M | 10.99M | 13.93M | 12.7M | 10.89M | 12.18M |
| Revenue Growth % | 0.04% | -0.23% | 0.2% | 0.06% | -0.01% | -0.19% | 0.27% | -0.09% | -0.14% | 0.12% |
| Cost of Goods Sold | 5.2M | 4.88M | 5.3M | 5.67M | 5.66M | 4.87M | 5.75M | 6M | 5.48M | 5.72M |
| COGS % of Revenue | 0.37% | 0.45% | 0.41% | 0.41% | 0.42% | 0.44% | 0.41% | 0.47% | 0.5% | 0.47% |
| Gross Profit | 8.8M | 5.89M | 7.67M | 8.1M | 7.94M | 6.11M | 8.18M | 6.7M | 5.41M | 6.46M |
| Gross Margin % | 0.63% | 0.55% | 0.59% | 0.59% | 0.58% | 0.56% | 0.59% | 0.53% | 0.5% | 0.53% |
| Gross Profit Growth % | 0.08% | -0.33% | 0.3% | 0.06% | -0.02% | -0.23% | 0.34% | -0.18% | -0.19% | 0.2% |
| Operating Expenses | 2.51M | 2.5M | 2.43M | 2.52M | 2.55M | 2.48M | 2.51M | 2.66M | 2.54M | 2.81M |
| OpEx % of Revenue | 0.18% | 0.23% | 0.19% | 0.18% | 0.19% | 0.23% | 0.18% | 0.21% | 0.23% | 0.23% |
| Selling, General & Admin | 1.86M | 1.85M | 1.79M | 2.12M | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A % of Revenue | 0.13% | 0.17% | 0.14% | 0.15% | - | - | - | - | - | - |
| Research & Development | 648.21K | 651.83K | 646.08K | 399.52K | 397.39K | 451.21K | 478.64K | 490.77K | 463.99K | 456.78K |
| R&D % of Revenue | 0.05% | 0.06% | 0.05% | 0.03% | 0.03% | 0.04% | 0.03% | 0.04% | 0.04% | 0.04% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 2.15M | 2.03M | 2.04M | 2.17M | 2.08M | 2.36M |
| Operating Income | 6.29M | 3.39M | 5.24M | 5.58M | 5.4M | 3.64M | 5.67M | 4.04M | 2.86M | 3.65M |
| Operating Margin % | 0.45% | 0.31% | 0.4% | 0.41% | 0.4% | 0.33% | 0.41% | 0.32% | 0.26% | 0.3% |
| Operating Income Growth % | 0.15% | -0.46% | 0.54% | 0.07% | -0.03% | -0.33% | 0.56% | -0.29% | -0.29% | 0.27% |
| EBITDA | 6.47M | 3.58M | 5.44M | 5.77M | 5.57M | 3.8M | 5.81M | 4.17M | 2.97M | 3.74M |
| EBITDA Margin % | 0.46% | 0.33% | 0.42% | 0.42% | 0.41% | 0.35% | 0.42% | 0.33% | 0.27% | 0.31% |
| EBITDA Growth % | 0.14% | -0.45% | 0.52% | 0.06% | -0.03% | -0.32% | 0.53% | -0.28% | -0.29% | 0.26% |
| D&A (Non-Cash Add-back) | 173.48K | 187.03K | 200.68K | 191.94K | 175.81K | 165.26K | 145.98K | 135.4K | 105.68K | 95.89K |
| EBIT | 6.29M | 3.39M | 5.24M | 5.58M | 5.4M | 3.64M | 5.67M | 4.04M | 2.86M | 3.65M |
| Net Interest Income | 0 | 0 | 0 | 0 | 203.33K | 226.25K | 233.86K | -1.38M | 306.65K | 434.68K |
| Interest Income | 0 | 0 | 0 | 0 | 203.33K | 226.25K | 233.86K | 236.69K | 306.65K | 434.68K |
| Interest Expense | 0 | 0 | 0 | 227.98K | - | 0 | 0 | 1.62M | 0 | 0 |
| Other Income/Expense | 331.83K | 306.5K | 315.17K | -113.99K | 634.4K | 524.83K | 210.84K | -809.55K | 387.75K | 461.67K |
| Pretax Income | 6.63M | 3.7M | 5.55M | 5.47M | 6.03M | 4.16M | 5.88M | 3.23M | 3.25M | 4.11M |
| Pretax Margin % | 0.47% | 0.34% | 0.43% | 0.4% | 0.44% | 0.38% | 0.42% | 0.25% | 0.3% | 0.34% |
| Income Tax | 2.02M | 1.11M | 1.71M | 1.11M | 1.27M | 856.02K | 1.22M | 658.17K | 669.41K | 857.58K |
| Effective Tax Rate % | 0.7% | 0.7% | 0.69% | 0.8% | 0.79% | 0.79% | 0.79% | 0.8% | 0.79% | 0.79% |
| Net Income | 4.61M | 2.58M | 3.84M | 4.35M | 4.76M | 3.3M | 4.66M | 2.57M | 2.58M | 3.25M |
| Net Margin % | 0.33% | 0.24% | 0.3% | 0.32% | 0.35% | 0.3% | 0.33% | 0.2% | 0.24% | 0.27% |
| Net Income Growth % | 0.14% | -0.44% | 0.49% | 0.13% | 0.09% | -0.31% | 0.41% | -0.45% | 0% | 0.26% |
| Net Income (Continuing) | 4.61M | 2.58M | 3.84M | 4.35M | 4.76M | 3.3M | 4.66M | 2.57M | 2.58M | 3.25M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 1.00 | 0.56 | 0.84 | 0.95 | 1.04 | 0.72 | 1.01 | 0.56 | 0.56 | 0.71 |
| EPS Growth % | 0.14% | -0.44% | 0.5% | 0.13% | 0.09% | -0.31% | 0.4% | -0.45% | 0% | 0.27% |
| EPS (Basic) | 1.00 | 0.56 | 0.84 | 0.95 | 1.04 | 0.72 | 1.01 | 0.56 | 0.56 | 0.71 |
| Diluted Shares Outstanding | 4.59M | 4.59M | 4.59M | 4.58M | 4.59M | 4.59M | 4.59M | 4.59M | 4.59M | 4.59M |
| Basic Shares Outstanding | 4.59M | 4.59M | 4.59M | 4.58M | 4.59M | 4.59M | 4.59M | 4.59M | 4.59M | 4.59M |
| Dividend Payout Ratio | 1% | 1.33% | 1.69% | 1.11% | 1.06% | 1.08% | 1.11% | 1.22% | 0.18% | 0.85% |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 14.52M | 13.97M | 11.85M | 11.69M | 11.57M | 11.25M | 11.58M | 9.97M | 12.25M | 12.67M |
| Cash & Short-Term Investments | 11.8M | 10.64M | 8.45M | 8.17M | 7.92M | 8.18M | 8.17M | 6.48M | 9.09M | 9.4M |
| Cash Only | 1.08M | 424.3K | 724.72K | 550.13K | 1.05M | 591.44K | 531.21K | 830.45K | 8.24M | 1.88M |
| Short-Term Investments | 10.72M | 10.22M | 7.72M | 7.62M | 6.87M | 7.59M | 7.64M | 5.65M | 851.32K | 7.52M |
| Accounts Receivable | 934.75K | 1.6M | 1.91M | 1.67M | 2.1M | 1.39M | 1.81M | 1.43M | 1.57M | 1.43M |
| Days Sales Outstanding | 24.36 | 54.12 | 53.63 | 44.34 | 56.32 | 46.1 | 47.52 | 41.03 | 52.54 | 42.8 |
| Inventory | 1.29M | 1.26M | 1.34M | 1.48M | 1.22M | 1.42M | 1.41M | 1.67M | 1.22M | 1.45M |
| Days Inventory Outstanding | 90.77 | 93.88 | 92.3 | 95.46 | 78.54 | 106.06 | 89.59 | 101.78 | 81.5 | 92.63 |
| Other Current Assets | 329.07K | 135.32K | 157.96K | 159.36K | 170.47K | 161.21K | 0 | 201.85K | 191.71K | 207.8K |
| Total Non-Current Assets | 1.17M | 1.15M | 1M | 857.57K | 795.53K | 673.66K | 658.86K | 669.71K | 670.13K | 1.13M |
| Property, Plant & Equipment | 1.1M | 1.09M | 942.89K | 827.92K | 780.71K | 673.66K | 658.86K | 559.16K | 619.2K | 956.39K |
| Fixed Asset Turnover | 12.78x | 9.88x | 13.75x | 16.63x | 17.42x | 16.31x | 21.14x | 22.71x | 17.58x | 12.74x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 14.82K | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | -401.68K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | -43.89K | -192.84K | -111.7K | -223.94K | 14.82K | -151.68K | -83.22K | 0 | 0 | 0 |
| Total Assets | 15.69M | 15.12M | 12.85M | 12.54M | 12.36M | 11.92M | 12.24M | 10.64M | 12.92M | 13.8M |
| Asset Turnover | 0.89x | 0.71x | 1.01x | 1.10x | 1.10x | 0.92x | 1.14x | 1.19x | 0.84x | 0.88x |
| Asset Growth % | -0.02% | -0.04% | -0.15% | -0.02% | -0.01% | -0.04% | 0.03% | -0.13% | 0.21% | 0.07% |
| Total Current Liabilities | 988.37K | 1.05M | 1.42M | 1.37M | 1.34M | 1.41M | 2.34M | 1.37M | 1.53M | 1.91M |
| Accounts Payable | 96.81K | 82.82K | 354.29K | 186.8K | 71.39K | 31.8K | 410.89K | 30.41K | 134.45K | 425K |
| Days Payables Outstanding | 6.79 | 6.19 | 24.39 | 12.03 | 4.61 | 2.38 | 26.09 | 1.85 | 8.96 | 27.11 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 190.16K | 0 | 15.5K | 0 |
| Other Current Liabilities | 105.93K | 215.98K | 314.54K | 299.25K | 373.94K | 321.74K | 898.4K | 638.98K | 543.85K | 681.73K |
| Current Ratio | 14.69x | 13.36x | 8.33x | 8.55x | 8.61x | 7.95x | 4.95x | 7.26x | 7.99x | 6.62x |
| Quick Ratio | 13.38x | 12.15x | 7.39x | 7.47x | 7.71x | 6.95x | 4.35x | 6.04x | 7.19x | 5.86x |
| Cash Conversion Cycle | 108.33 | 141.81 | 121.53 | 127.76 | 130.25 | 149.78 | 111.01 | 140.96 | 125.08 | 108.32 |
| Total Non-Current Liabilities | 150.39K | 252.13K | 33.85K | 253.58K | 386.86K | 151.68K | 83.22K | 0 | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 118.01K | 252.13K | 33.85K | 253.58K | 386.86K | 151.68K | 83.22K | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.14M | 1.3M | 1.46M | 1.62M | 1.73M | 1.57M | 2.42M | 1.37M | 1.53M | 1.91M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -1.08M | -424.3K | -724.72K | -550.13K | -1.05M | -591.44K | -531.21K | -830.45K | -8.24M | -1.88M |
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -0.17x | -0.12x | -0.13x | -0.10x | -0.19x | -0.16x | -0.09x | -0.20x | -2.78x | -0.50x |
| Interest Coverage | - | - | - | 24.48x | - | - | - | 2.49x | - | - |
| Total Equity | 14.55M | 13.82M | 11.4M | 10.92M | 10.63M | 10.35M | 9.82M | 9.27M | 11.39M | 11.88M |
| Equity Growth % | -0.01% | -0.05% | -0.18% | -0.04% | -0.03% | -0.03% | -0.05% | -0.06% | 0.23% | 0.04% |
| Book Value per Share | 3.17 | 3.01 | 2.48 | 2.38 | 2.31 | 2.25 | 2.14 | 2.02 | 2.48 | 2.59 |
| Total Shareholders' Equity | 14.55M | 13.82M | 11.4M | 10.92M | 10.63M | 10.35M | 9.82M | 9.27M | 11.39M | 11.88M |
| Common Stock | 459.43K | 459.43K | 459.43K | 459.43K | 459.43K | 459.43K | 459.43K | 459.43K | 459.43K | 459.43K |
| Retained Earnings | 14.02M | 13.19M | 10.47M | 10.47M | 10.17M | 9.89M | 9.36M | 8.81M | 10.93M | 11.42M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 72.36K | 175.63K | 466.02K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 5.2M | 2.29M | 3.99M | 4.95M | 4.48M | 3.59M | 5.31M | 2.53M | 3.14M | 3.47M |
| Operating CF Margin % | 0.37% | 0.21% | 0.31% | 0.36% | 0.33% | 0.33% | 0.38% | 0.2% | 0.29% | 0.28% |
| Operating CF Growth % | 0.16% | -0.56% | 0.74% | 0.24% | -0.1% | -0.2% | 0.48% | -0.52% | 0.25% | 0.1% |
| Net Income | 4.61M | 2.58M | 3.84M | 4.35M | 4.76M | 3.3M | 4.66M | 2.57M | 2.58M | 3.25M |
| Depreciation & Amortization | 173.48K | 187.03K | 200.68K | 191.94K | 175.81K | 165.26K | 145.98K | 135.4K | 105.68K | 95.89K |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | -22.37K | 59.71K | -31.76K | 219.73K | 133.27K | -235.17K | -68.46K | -193.77K | 59.61K | -124.47K |
| Other Non-Cash Items | -21.24K | 8.29K | -29.02K | 341.65K | -411.79K | -305.75K | 14.45K | 1.08M | -111.49K | -43.53K |
| Working Capital Changes | 464.68K | -546.75K | 8.1K | -155.24K | -182.89K | 664.92K | 562.77K | -1.06M | 509.3K | 287.49K |
| Change in Receivables | 679.75K | -671.53K | -311.69K | 237.17K | -430.13K | 717.87K | -431.88K | 385.96K | -135.87K | 140.71K |
| Change in Inventory | -56.49K | 37.83K | -84.71K | -141.63K | 249.87K | -198.5K | 4.98K | -290.22K | 465.51K | -214.28K |
| Change in Payables | -44.3K | -13.99K | 271.46K | -167.49K | -115.41K | -39.59K | 379.09K | -380.48K | 104.03K | 290.55K |
| Cash from Investing | -1.67M | 490.24K | 2.82M | -308.76K | 1.07M | -468.68K | -183.47K | 897.56K | 4.73M | -7.08M |
| Capital Expenditures | -62.57K | -166.69K | -38.15K | -74.99K | -113.77K | -43.4K | -116.38K | -75.18K | -165.72K | -433.08K |
| CapEx % of Revenue | 0% | 0.02% | 0% | 0.01% | 0.01% | 0% | 0.01% | 0.01% | 0.02% | 0.04% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -60.18K | -167.7K | -4.85K | -70.79K | -113.77K | -43.4K | -116.38K | 0 | 10K | 0 |
| Cash from Financing | -4.47M | -3.44M | -6.51M | -4.82M | -5.05M | -3.58M | -5.19M | -3.12M | -459.39K | -2.76M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | -4.59M | -3.44M | -6.51M | -4.82M | -5.05M | -3.58M | -5.19M | -3.12M | -459.39K | -2.76M |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 120.85K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | 5.14M | 2.12M | 3.95M | 4.88M | 4.36M | 3.55M | 5.2M | 2.45M | 2.98M | 3.03M |
| FCF Margin % | 0.37% | 0.2% | 0.3% | 0.35% | 0.32% | 0.32% | 0.37% | 0.19% | 0.27% | 0.25% |
| FCF Growth % | 0.16% | -0.59% | 0.86% | 0.23% | -0.11% | -0.19% | 0.46% | -0.53% | 0.22% | 0.02% |
| FCF per Share | 1.12 | 0.46 | 0.86 | 1.06 | 0.95 | 0.77 | 1.13 | 0.53 | 0.65 | 0.66 |
| FCF Conversion (FCF/Net Income) | 1.13x | 0.89x | 1.04x | 1.14x | 0.94x | 1.09x | 1.14x | 0.98x | 1.22x | 1.07x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 1.6M | 1.15M | 1.1M | 1.02M | 1.1M | 1.13M | 600K | 1.05M |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 31.46% | 18.2% | 30.49% | 39% | 44.18% | 31.5% | 46.18% | 26.92% | 24.99% | 27.94% |
| Return on Invested Capital (ROIC) | 36.06% | 18.93% | 32.63% | 39.77% | 40.55% | 28.19% | 44.62% | 34.16% | 37.08% | 41.59% |
| Gross Margin | 62.86% | 54.69% | 59.12% | 58.84% | 58.4% | 55.65% | 58.74% | 52.78% | 49.66% | 53.03% |
| Net Margin | 32.89% | 23.95% | 29.64% | 31.61% | 35.01% | 30.08% | 33.44% | 20.23% | 23.71% | 26.69% |
| Interest Coverage | - | - | - | 24.48x | - | - | - | 2.49x | - | - |
| FCF Conversion | 1.13x | 0.89x | 1.04x | 1.14x | 0.94x | 1.09x | 1.14x | 0.98x | 1.22x | 1.07x |
| Revenue Growth | 4.14% | -23.06% | 20.33% | 6.18% | -1.24% | -19.21% | 26.79% | -8.84% | -14.28% | 11.91% |
| 2012 | 2013 | 2014 | 2015 | 2016 | |
|---|---|---|---|---|---|
| Personal Care | 9.44M | 11.46M | 9.42M | 9.92M | 4.92M |
| Personal Care Growth | - | 21.41% | -17.79% | 5.32% | -50.45% |
| Pharmaceuticals | 1.52M | 916.93K | 1.69M | 1.86M | 3.44M |
| Pharmaceuticals Growth | - | -39.86% | 83.94% | 10.53% | 84.71% |
| Medical | 2.9M | 3.03M | 2.49M | 2.2M | 2.62M |
| Medical Growth | - | 4.28% | -17.65% | -11.64% | 19.09% |
| Industrial And Other | 153.5K | 164.01K | 169.49K | 174.36K | 159.94K |
| Industrial And Other Growth | - | 6.85% | 3.34% | 2.88% | -8.27% |
United-Guardian, Inc. (UG) has a price-to-earnings (P/E) ratio of 8.8x. This may indicate the stock is undervalued or faces growth challenges.
United-Guardian, Inc. (UG) reported $10.1M in revenue for fiscal year 2024. This represents a 30% decrease from $14.3M in 2011.
United-Guardian, Inc. (UG) grew revenue by 11.9% over the past year. This is steady growth.
Yes, United-Guardian, Inc. (UG) is profitable, generating $2.0M in net income for fiscal year 2024 (26.7% net margin).
Yes, United-Guardian, Inc. (UG) pays a dividend with a yield of 9.58%. This makes it attractive for income-focused investors.
United-Guardian, Inc. (UG) has a return on equity (ROE) of 27.9%. This is excellent, indicating efficient use of shareholder capital.
United-Guardian, Inc. (UG) generated $1.6M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.